Large cell lung carcinoma (LCLC) accounts for 5-10% of all lung cancers and is a poorly differentiated non-small cell lung cancer (NSCLC) type. It is a diagnosis of exclusion — tumors that do not show glandular (adeno), squamous, or small cell differentiation are categorized here. It typically presents as a large peripheral mass and is often >4 cm at diagnosis. It has aggressive biology with rapid growth and early metastatic tendency. Necrosis is common. Five-year survival is 50-60% in stage I and less than 5% in stage IV. The neuroendocrine subtype (LCNEC) is even more aggressive and is treated similarly to small cell carcinoma.
Age Range
50-80
Peak Age
65
Gender
Male predominant
Prevalence
Uncommon
Large cell carcinoma is a poorly differentiated tumor composed of large pleomorphic cells. It does not show glandular, squamous, or neuroendocrine differentiation — hence it is a diagnosis of exclusion. Cells are large with prominent nuclei and abundant cytoplasm. It typically originates from peripheral airways and grows rapidly. Intense neovascularization and rapid growth lead to central ischemic necrosis — appearing as large necrotic areas on CT. Due to peripheral location, pleural invasion and pleural effusion may develop early. Hematogenous spread is early — brain, bone, and liver are the most common metastatic sites. On immunohistochemistry, TTF-1 and napsin-A are negative (adeno markers), p40 and p63 are negative (squamous markers), Ki-67 proliferation index is high (50-80%).
A peripheral mass >4 cm with lobulated (non-spiculated) margins and prominent central necrosis is the signature finding of large cell carcinoma. On contrast-enhanced CT, peripheral rim enhancement pattern (viable tumor) and central non-enhancing area (necrosis) are seen. Distinguished from spiculated margins and GGO component of adenocarcinoma, central cavitation of squamous cell carcinoma, and massive LAP of small cell carcinoma.
Large peripheral mass: Typically 5-10 cm, lobulated or smooth margins. Prominent central necrosis (low attenuation, 10-20 HU). Peripheral solid component preserved. Spiculated margins rare — differs from adenocarcinoma. Mass is typically spherical or ovoid. Pleural contact/invasion may develop early.
Report Sentence
A ___ cm peripheral, lobulated mass with prominent central necrosis in the right/left lung is identified, and a rapidly growing poorly differentiated malignancy (large cell carcinoma) should be considered.
Peripheral rim enhancement on contrast-enhanced CT: Viable peripheral tumor tissue enhances markedly while central necrotic area does not enhance. Irregular thickness peripheral enhancing rim. Vascular invasion and pleural enhancement may accompany.
Report Sentence
The mass demonstrates irregular-thickness peripheral rim enhancement on contrast-enhanced CT with a non-enhancing central area (necrosis); consistent with malignant lesion.
High FDG uptake on PET-CT: SUVmax typically >5, often ranging 8-20. Intense uptake in peripheral viable tumor tissue, absence of uptake in central necrotic area (photopenia). High metabolic activity due to aggressive biology.
Report Sentence
The peripheral mass demonstrates intense FDG uptake on PET-CT (SUVmax: ___) with marked metabolic activity in viable tumor tissue and photopenia in the central necrotic area.
Heterogeneous T2 signal on MRI: Intermediate T2 signal in solid tumor component, high T2 signal in necrotic areas, high T1 signal in hemorrhagic areas. Marked diffusion restriction on DWI (high cellularity). Complementary to CT for chest wall and mediastinal invasion assessment.
Report Sentence
The mass demonstrates heterogeneous signal on MRI with intermediate T2 signal in the solid component, high T2 signal in necrotic areas, and marked diffusion restriction on DWI.
Pleural invasion and effusion: Early pleural invasion due to peripheral location. Pleural thickening, nodular pleural enhancement, pleural effusion. Effusion is frequently hemorrhagic (high attenuation, >20 HU). Pleural invasion affects surgical resectability.
Report Sentence
Nodular thickening at the pleural surface adjacent to the peripheral mass with ipsilateral pleural effusion (attenuation: ___ HU) is identified, and pleural invasion should be considered.
Criteria
Neuroendocrine morphology (rosettes, trabeculae) + neuroendocrine markers (chromogranin, synaptophysin positive). High mitotic index (>10/10 HPF).
Distinct Features
Most aggressive subtype — prognosis similar to small cell carcinoma. Peripheral large necrotic mass. Very high FDG uptake on PET-CT. Treated per SCLC protocol. 5-year survival 15-25%.
Criteria
Basaloid cell morphology, peripheral palisading, comedoid necrosis. No squamous or glandular differentiation on immunohistochemistry.
Distinct Features
Aggressive biology, rapid growth. Large peripheral mass with prominent necrosis on CT. Distinguished from basaloid variant of squamous cell carcinoma by immunohistochemistry.
Criteria
Undifferentiated carcinoma islands within prominent lymphocytic infiltration. EBV association common (Asian population). Rare subtype.
Distinct Features
Better prognosis than other large cell carcinoma subtypes. Peripheral mass on CT, lymphadenopathy common. Young age, Southeast Asian predilection. Good response to immunotherapy.
Distinguishing Feature
Adenocarcinoma has spiculated margins, may have GGO component, necrosis less prominent. Large cell carcinoma has lobulated/smooth margins, no GGO component, very prominent necrosis. Definitive differentiation is histopathological.
Distinguishing Feature
Squamous cell carcinoma is usually central, cavitation common, endobronchial growth pattern. Large cell carcinoma is usually peripheral, necrosis present but cavitation (air-filled space) less common, no endobronchial component.
Distinguishing Feature
Metastases are usually multiple, bilateral, smooth-margined. Single large necrotic metastasis may be indistinguishable from primary large cell carcinoma on imaging — known extrathoracic malignancy history is critical. Primary tumor localization on PET-CT is helpful.
Distinguishing Feature
Abscess has thin wall (<5 mm), smooth inner surface, surrounding consolidation, fever + leukocytosis. Large cell carcinoma has thick wall (>15 mm), irregular inner surface, no fever. Response to antibiotic treatment favors abscess.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralSurgical resection (lobectomy) is curative in early-stage large cell carcinoma. Platinum-based chemotherapy + immunotherapy is standard for advanced stages. Small cell carcinoma protocol may be applied for the LCNEC subtype. Targeted therapy options are limited but PD-L1 expression is generally high — immunotherapy response rates are good. Rapid diagnosis and treatment initiation are important due to aggressive biology. Multidisciplinary tumor board evaluation is required. Histopathological subtyping (LCNEC vs others) changes treatment strategy.
Large cell carcinoma has aggressive behavior and worse prognosis compared to other NSCLC subtypes. Treatment is surgery (early stage) and chemotherapy/immunotherapy. Molecular profiling guides treatment selection.